These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 28326839)

  • 1. Entinostat: a promising treatment option for patients with advanced breast cancer.
    Connolly RM; Rudek MA; Piekarz R
    Future Oncol; 2017 Jun; 13(13):1137-1148. PubMed ID: 28326839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.
    Connolly RM; Zhao F; Miller KD; Lee MJ; Piekarz RL; Smith KL; Brown-Glaberman UA; Winn JS; Faller BA; Onitilo AA; Burkard ME; Budd GT; Levine EG; Royce ME; Kaufman PA; Thomas A; Trepel JB; Wolff AC; Sparano JA
    J Clin Oncol; 2021 Oct; 39(28):3171-3181. PubMed ID: 34357781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Entinostat for the treatment of breast cancer.
    Trapani D; Esposito A; Criscitiello C; Mazzarella L; Locatelli M; Minchella I; Minucci S; Curigliano G
    Expert Opin Investig Drugs; 2017 Aug; 26(8):965-971. PubMed ID: 28718331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor.
    Yardley DA; Ismail-Khan RR; Melichar B; Lichinitser M; Munster PN; Klein PM; Cruickshank S; Miller KD; Lee MJ; Trepel JB
    J Clin Oncol; 2013 Jun; 31(17):2128-35. PubMed ID: 23650416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer.
    Masuda N; Tamura K; Yasojima H; Shimomura A; Sawaki M; Lee MJ; Yuno A; Trepel J; Kimura R; Nishimura Y; Saji S; Iwata H
    BMC Cancer; 2021 Nov; 21(1):1269. PubMed ID: 34819039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors.
    Ngamphaiboon N; Dy GK; Ma WW; Zhao Y; Reungwetwattana T; DePaolo D; Ding Y; Brady W; Fetterly G; Adjei AA
    Invest New Drugs; 2015 Feb; 33(1):225-32. PubMed ID: 25371323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
    Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
    Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase I Study and Pilot Efficacy Analysis of Entinostat, a Novel Histone Deacetylase Inhibitor, in Chinese Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer.
    Wang J; Zhang Q; Li Q; Mu Y; Jing J; Li H; Li W; Wang J; Yu G; Wang X; Ouyang Q; Hao J; Lu L; Zhou L; Guan J; Li Q; Xu B
    Target Oncol; 2021 Sep; 16(5):591-599. PubMed ID: 34196874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours.
    Pili R; Salumbides B; Zhao M; Altiok S; Qian D; Zwiebel J; Carducci MA; Rudek MA
    Br J Cancer; 2012 Jan; 106(1):77-84. PubMed ID: 22134508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Entinostat plus exemestane has activity in ER+ advanced breast cancer.
    Cancer Discov; 2013 Jul; 3(7):OF17. PubMed ID: 23847360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study.
    Connolly RM; Li H; Jankowitz RC; Zhang Z; Rudek MA; Jeter SC; Slater SA; Powers P; Wolff AC; Fetting JH; Brufsky A; Piekarz R; Ahuja N; Laird PW; Shen H; Weisenberger DJ; Cope L; Herman JG; Somlo G; Garcia AA; Jones PA; Baylin SB; Davidson NE; Zahnow CA; Stearns V
    Clin Cancer Res; 2017 Jun; 23(11):2691-2701. PubMed ID: 27979916
    [No Abstract]   [Full Text] [Related]  

  • 12. The histone deacetylase inhibitor Entinostat enhances polymer-mediated transgene expression in cancer cell lines.
    Elmer JJ; Christensen MD; Barua S; Lehrman J; Haynes KA; Rege K
    Biotechnol Bioeng; 2016 Jun; 113(6):1345-1356. PubMed ID: 26614912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical rationale for entinostat in embryonal rhabdomyosarcoma.
    Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Pal R; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
    Skelet Muscle; 2019 May; 9(1):12. PubMed ID: 31113472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models.
    Kurmasheva RT; Bandyopadhyay A; Favours E; Del Pozo V; Ghilu S; Phelps DA; Erickson SW; Peer CJ; Figg WD; Smith MA; Houghton PJ
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27820. PubMed ID: 31099166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment.
    Lim B; Murthy RK; Lee J; Jackson SA; Iwase T; Davis DW; Willey JS; Wu J; Shen Y; Tripathy D; Alvarez R; Ibrahim NK; Brewster AM; Barcenas CH; Brown PH; Giordano SH; Moulder SL; Booser DJ; Moscow JA; Piekarz R; Valero V; Ueno NT
    Br J Cancer; 2019 Jun; 120(12):1105-1112. PubMed ID: 31097774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
    Frys S; Simons Z; Hu Q; Barth MJ; Gu JJ; Mavis C; Skitzki J; Song L; Czuczman MS; Hernandez-Ilizaliturri FJ
    Br J Haematol; 2015 May; 169(4):506-19. PubMed ID: 25712263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Entinostat (SNDX-275) for the treatment of non-small cell lung cancer.
    Ruiz R; Raez LE; Rolfo C
    Expert Opin Investig Drugs; 2015; 24(8):1101-9. PubMed ID: 26098363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer.
    Schech AJ; Shah P; Yu S; Sabnis GJ; Goloubeva O; Rosenblatt P; Kazi A; Chumsri S; Brodie A
    Breast Cancer Res Treat; 2015 Aug; 152(3):499-508. PubMed ID: 26133921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies.
    van Tilburg CM; Witt R; Heiss M; Pajtler KW; Plass C; Poschke I; Platten M; Harting I; Sedlaczek O; Freitag A; Meyrath D; Taylor L; Balasubramanian GP; J├Ąger N; Pfaff E; Jones BC; Milde T; Pfister SM; Jones DTW; Kopp-Schneider A; Witt O
    BMC Cancer; 2020 Jun; 20(1):523. PubMed ID: 32503469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Entinostat for treatment of solid tumors and hematologic malignancies.
    Knipstein J; Gore L
    Expert Opin Investig Drugs; 2011 Oct; 20(10):1455-67. PubMed ID: 21888556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.